A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). The therapeutic agents in our small molecule product candidates are typically well-understood and marketed drugs that are effective but are limited by pharmacokinetic (“PK”) profiles that can include toxicity, side effects and short half-life. We believe that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood. We believe that POZ technology can be applied to small molecules, proteins, ADCs, and other classes of molecules.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 3.2M | - | - | - |
| Net Income | -19M | -11M | 5.3M | -10M | -8.7M | -11M |
| EPS | $-1.87 | $-1.51 | $0.73 | $-9.85 | $-8.16 | $-10.36 |
| Free Cash Flow | 0 | -17M | -3.0M | -5.9M | -7.9M | -7.8M |
| ROIC | -148.7% | -200.3% | -27.6% | -170.0% | -198.7% | -203.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | -0.09 | -0.61 | -0.51 | -1.77 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -23M | -17M | -3.1M | -7.0M | -7.9M | -10M |
| Operating Margin | 0.0% | - | -99.2% | - | - | - |
| ROE | -1056.0% | -1738.1% | - | - | - | - |
| Shares Outstanding | 11M | 7M | 7M | 1M | 1M | 1M |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | 3.2M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -6.7M | -11M | -13M | -10M | -7.9M | -7.0M | -3.1M | -17M | -23M |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | -99.2% | N/A | 0.0% |
| Net Income | -6.6M | -7.5M | -12M | -11M | -8.7M | -10M | 5.3M | -11M | -19M |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | 167.1% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||
| ROIC | -90.4% | -119.3% | N/M | N/M | -198.7% | -170.0% | -27.6% | N/M | -148.7% |
| ROE | -90.4% | -101.9% | -251.5% | N/A | N/A | N/A | N/A | -1738.1% | -1056.0% |
| ROA | -68.3% | -73.9% | -134.2% | -276.8% | -275.0% | -327.2% | 58.8% | -142.0% | -149.7% |
| Cash Flow | |||||||||
| Op. Cash Flow | -6.3M | -8.0M | -10M | -7.8M | -7.9M | -5.9M | -2.5M | -17M | -17M |
| Free Cash Flow | -6.3M | -8.0M | -11M | -7.8M | -7.9M | -5.9M | -3.0M | -17M | 0 |
| Owner Earnings | -6.6M | -9.3M | -12M | -9.4M | -9.0M | -6.8M | -2.6M | -20M | -19M |
| CapEx | 1K | 21K | 641K | 20K | 0 | 0 | 504K | 22K | 0 |
| Maint. CapEx | 165K | 58K | 91K | 699K | 131K | 132K | 90K | 194K | 194K |
| Growth CapEx | 0 | 0 | 550K | 0 | N/A | N/A | 414K | 0 | 0 |
| D&A | 165K | 58K | 91K | 699K | 131K | 132K | 90K | 194K | 194K |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 114K | 1.3M | 1.9M | 909K | 999K | 760K | 25K | 2.6M | 2.6M |
| Debt Repayment | 0 | 0 | 0 | 157K | 0 | 0 | 48K | 35K | 35K |
| Balance Sheet | |||||||||
| Net Debt | N/A | N/A | N/A | N/A | 5.5M | 9.8M | -4.6M | -3.7M | -8.6M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 8.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | 6.1M | 10M | 3.0M | 0 | N/A |
| Debt/Equity | 0.18 | 0.33 | 2.18 | -1.77 | -0.51 | -0.61 | -0.09 | 0.00 | 0.00 |
| Interest Coverage | -555.3 | -96.9 | -433.1 | -25.0 | -7.2 | -2.1 | -5.6 | -32.4 | -32.4 |
| Equity | 7.3M | 7.4M | 2.2M | -5.1M | -12M | -17M | -32M | 641K | 1.8M |
| Total Assets | 9.6M | 11M | 7.4M | 3.9M | 3.2M | 3.2M | 9.0M | 6.7M | 12M |
| Total Liabilities | 1.3M | 2.4M | 4.8M | 9.0M | 15M | 20M | 4.9M | 6.2M | 11M |
| Intangibles | 3.7M | 5.4M | 4.3M | 3.2M | 1.7M | 1.5M | N/A | N/A | N/A |
| Retained Earnings | -67M | -74M | -86M | -97M | -106M | -116M | -33M | -44M | -44M |
| Working Capital | 6.8M | 6.4M | 757K | -3.1M | -6.7M | -7.6M | 6.2M | 3.3M | 3.3M |
| Current Assets | 7.6M | 7.9M | 4.1M | 2.3M | 2.2M | 2.5M | 7.6M | 5.7M | 5.7M |
| Current Liabilities | 768K | 1.4M | 3.3M | 5.4M | 9.0M | 10M | 1.4M | 2.4M | 2.4M |
| Per Share Data | |||||||||
| EPS | -7.50 | -7.50 | -11.79 | -10.36 | -8.16 | -9.85 | 0.73 | -1.51 | -1.87 |
| Owner EPS | -7.48 | -9.34 | -11.79 | -8.98 | -8.46 | -6.43 | -0.36 | -2.70 | -1.81 |
| Book Value | 8.30 | 7.45 | 2.15 | -4.88 | -11.13 | -16.20 | -4.47 | 0.09 | 0.17 |
| Cash Flow/Share | -7.16 | -7.99 | -9.85 | -7.45 | -7.39 | -5.59 | -0.34 | -2.32 | -1.72 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.9M | 1.0M | 1.0M | 1.0M | 1.1M | 1.1M | 7.2M | 7.4M | 10.7M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 19.1 | N/A | -1.0 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 13.9 | 28.9 | N/A | N/A | N/A | N/A | 64.9 | 11.7 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | 51.9 | N/A | N/A |
| FCF Yield | N/A | -7.8% | -16.9% | -12.7% | -37.0% | -28.5% | -3.0% | -41.2% | N/A |
| Market Cap | N/A | 103M | 64M | 62M | 21M | 21M | 101M | 42M | 21M |
| Avg. Price | N/A | 130.21 | 109.05 | 43.11 | 48.11 | 25.18 | 22.65 | 9.45 | 1.93 |
| Year-End Price | N/A | 103.21 | 62.14 | 58.93 | 20.00 | 19.64 | 13.96 | 5.64 | 1.93 |
Serina Therapeutics, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
Serina Therapeutics, Inc. (SER) has a 5-year average return on invested capital (ROIC) of -132.1%. This is below average and may indicate limited pricing power.
Serina Therapeutics, Inc. (SER) has a market capitalization of $21M. It is classified as a small-cap stock.
Serina Therapeutics, Inc. (SER) does not currently pay a regular dividend.
Serina Therapeutics, Inc. (SER) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Serina Therapeutics, Inc. (SER) generated $-17 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Serina Therapeutics, Inc. (SER) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Serina Therapeutics, Inc. (SER) reported earnings per share (EPS) of $-1.51 in its most recent fiscal year.
Serina Therapeutics, Inc. (SER) has a return on equity (ROE) of -1738.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 8 years of financial data for Serina Therapeutics, Inc. (SER), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Serina Therapeutics, Inc. (SER) has a book value per share of $0.09, based on its most recent annual SEC filing.